NEW YORK, Aug 16, 2020 (GLOBE NEWSWIRE) – Pomerantz LLP is investigating claims on behalf of investors in Reata Pharmaceuticals, Inc. (“Reata” or the “Company”) (NASDAQ: RETA). Such investors are encouraged to contact Robert S. Willoughby at email@example.com or extension 1 at 888-476-6529. 7980.
The investigation concerns whether Reata and any of its officers and / or directors have committed securities fraud or other illegal business practices.
(Click here for information on how to participate in the class action.)
On August 10, 2020, Reata announced in its quarterly report for the second quarter of 2020 that the US Food and Drug Administration ("FDA") "is not convinced that the results of MOXIe Part 2" of the company's study for the Assessment of Omaveloxolone for Treatment of Friedreich's Ataxia “will support a single trial approval with no additional evidence to convince the results. In preliminary comments for the meeting, the FDA stated that we need to conduct a second key study that confirms the mFARS results of the MOXIe Part 2 study with a similar level of impact. In this news, Reata's share price fell sharply during intraday trading on August 10, 2020.
The Pomerantz firm, with offices in New York, Chicago, Los Angeles and Paris, is recognized as one of the leading law firms in corporate, securities and antitrust litigation. Founded by the late Abraham L. Pomerantz, dean of class action lawsuit, Pomerantz pioneered class action lawsuits. Today, more than 80 years later, the Pomerantz company continues its tradition and fights for the rights of victims of securities fraud, fiduciary violations and corporate misconduct. The company has reclaimed numerous millions of dollars in damages on behalf of class members. See www.pomerantzlaw.com.
Robert S. Willoughby
888-476-6529 ext. 7980